ArticleWorld journal of surgical oncology2026
Omitting axillary lymph node dissection or not? A multicenter, retrospective study for breast cancer patients potentially eligible for abemaciclib since the SENOMAC trial.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe SENOMAC trial has resolved the longstanding clinical debate regarding the omission of axillary lymph node dissection (ALND) in patients with 1–2 positive sentinel lymph nodes (SLNs). However, the MonarchE trial demonstrated the benefit of abemaciclib as an adjuvant endocrine therapy for high-risk patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The inclusion criteria of MonarchE, particularly the requirement for pN2 status, may necessitate reconsideration of surgical interventions.
methodsThis study retrospectively included 711 patients with cT1-2N0M0, HR+/HER2-, and 1–2 positive SLNs in the Shanghai Jiao Tong University breast cancer database. All patients underwent further ALND. The study evaluated the proportion of patients with pathological stage upgrading to pN2 or pN3 after ALND, analyzed the independent predictors of high lymph node burden, and further evaluated the diagnostic efficacy of the SENOMAC nomogram in predicting high nodal burden.
resultsAmong the 711 patients, 17.6% were confirmed to be at pN2 or pN3 stage by ALND, meeting the criteria for adjuvant abemaciclib treatment. Multivariate analysis showed that the number of positive SLNs (OR = 5.267, 95% CI: 3.487–7.958) and the number of removed SLNs (OR = 0.839, 95% CI: 0.752–0.927) and tumor size (OR = 2.409, 95% CI: 1.615–3.594) were independent risk factors for predicting pN2/pN3. Patients with pN2-pN3 disease had significantly worse recurrence-free survival compared to those with pN1 disease (HR = 4.958, 95% CI: 1.786–13.762, p = 0.0017). The predictive performance of the SENOMAC nomogram in this cohort was AUC = 0.763 (95% CI: 0.712–0.814).
conclusions17.6% of patients with 1–2 positive SLNs and no additional high-risk factors were reclassified as high nodal burden after ALND. Given the relatively low prevalence of these cases, routinely performing ALND on all such patients has limited clinical benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.